149 related articles for article (PubMed ID: 12605968)
1. Posttherapy surveillance monitoring of cervical cancer by FDG-PET.
Grigsby PW; Siegel BA; Dehdashti F; Mutch DG
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):907-13. PubMed ID: 12605968
[TBL] [Abstract][Full Text] [Related]
2. FDG-PET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma.
Singh AK; Grigsby PW; Dehdashti F; Herzog TJ; Siegel BA
Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):489-93. PubMed ID: 12738325
[TBL] [Abstract][Full Text] [Related]
3. Metabolic response on post-therapy FDG-PET predicts patterns of failure after radiotherapy for cervical cancer.
Schwarz JK; Siegel BA; Dehdashti F; Grigsby PW
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):185-90. PubMed ID: 22014958
[TBL] [Abstract][Full Text] [Related]
4. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome.
Grigsby PW; Siegel BA; Dehdashti F; Rader J; Zoberi I
J Clin Oncol; 2004 Jun; 22(11):2167-71. PubMed ID: 15169804
[TBL] [Abstract][Full Text] [Related]
5. Improved prognostic value of 18F-FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer.
Miller TR; Pinkus E; Dehdashti F; Grigsby PW
J Nucl Med; 2003 Feb; 44(2):192-7. PubMed ID: 12571208
[TBL] [Abstract][Full Text] [Related]
6. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix.
Grigsby PW; Siegel BA; Dehdashti F
J Clin Oncol; 2001 Sep; 19(17):3745-9. PubMed ID: 11533097
[TBL] [Abstract][Full Text] [Related]
7. FDG-PET in carcinoma of the uterine cervix with endometrial extension.
Hope AJ; Saha P; Grigsby PW
Cancer; 2006 Jan; 106(1):196-200. PubMed ID: 16302228
[TBL] [Abstract][Full Text] [Related]
8. Preliminary report of using FDG-PET to detect extrapelvic lesions in cervical cancer patients with enlarged pelvic lymph nodes on MRI/CT.
Tsai CS; Chang TC; Lai CH; Tsai CC; Ng KK; Hsueh S; Yen TC; Hong JH
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1506-12. PubMed ID: 15050330
[TBL] [Abstract][Full Text] [Related]
9. A prospective randomized trial to study the impact of pretreatment FDG-PET for cervical cancer patients with MRI-detected positive pelvic but negative para-aortic lymphadenopathy.
Tsai CS; Lai CH; Chang TC; Yen TC; Ng KK; Hsueh S; Lee SP; Hong JH
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):477-84. PubMed ID: 19464824
[TBL] [Abstract][Full Text] [Related]
10. Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix.
Tran BN; Grigsby PW; Dehdashti F; Herzog TJ; Siegel BA
Gynecol Oncol; 2003 Sep; 90(3):572-6. PubMed ID: 13678726
[TBL] [Abstract][Full Text] [Related]
11. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy.
Miller TR; Grigsby PW
Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):353-9. PubMed ID: 12023139
[TBL] [Abstract][Full Text] [Related]
12. Lack of benefit of concurrent chemotherapy in patients with cervical cancer and negative lymph nodes by FDG-PET.
Grigsby PW; Mutch DG; Rader J; Herzog TJ; Zoberi I; Siegel BA; Dehdashti F
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):444-9. PubMed ID: 15667965
[TBL] [Abstract][Full Text] [Related]
13. Detection of early recurrence with 18F-FDG PET in patients with cervical cancer.
Ryu SY; Kim MH; Choi SC; Choi CW; Lee KH
J Nucl Med; 2003 Mar; 44(3):347-52. PubMed ID: 12620999
[TBL] [Abstract][Full Text] [Related]
14. Prognostic importance of lymph node-to-primary tumor standardized uptake value ratio in invasive squamous cell carcinoma of uterine cervix.
Chung HH; Cheon GJ; Kim JW; Park NH; Song YS
Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1862-1869. PubMed ID: 28534183
[TBL] [Abstract][Full Text] [Related]
15. (
Scher N; Castelli J; Depeursinge A; Bourhis J; Prior JO; Herrera FG; Ozsahin M
Cancer Radiother; 2018 May; 22(3):229-235. PubMed ID: 29650390
[TBL] [Abstract][Full Text] [Related]
16. The role of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG-PET) in the diagnosis of recurrence and lymph node metastasis of cervical cancer.
Umesaki N; Tanaka T; Miyama M; Kawabe J; Okamura T; Koyama K; Ochi H; Ogita S
Oncol Rep; 2000; 7(6):1261-4. PubMed ID: 11032926
[TBL] [Abstract][Full Text] [Related]
17. Maximum Standardized Uptake Value of Pelvic Lymph Nodes in [18F]-Fluorodeoxyglucose Positron Emission Tomography Is a Prognostic Factor for Para-Aortic Lymph Node Recurrence in Pelvic Node-Positive Cervical Cancer Treated With Definitive Chemoradiotherapy.
Kim DH; Kim WT; Bae JS; Ki YK; Park D; Suh DS; Kim KH; Lee JH; Lee JY; Jeon HS; Nam JH
Int J Gynecol Cancer; 2016 Sep; 26(7):1274-80. PubMed ID: 27465890
[TBL] [Abstract][Full Text] [Related]
18. Prognostic utility of squamous cell carcinoma antigen in carcinoma of the cervix: association with pre- and posttreatment FDG-PET.
Olsen JR; Dehdashti F; Siegel BA; Zighelboim I; Grigsby PW; Schwarz JK
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):772-7. PubMed ID: 20888130
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of pretreatment 18F-fluorodeoxyglucose uptake in patients with cervical cancer treated with definitive chemoradiotherapy.
Onal C; Reyhan M; Parlak C; Guler OC; Oymak E
Int J Gynecol Cancer; 2013 Jul; 23(6):1104-10. PubMed ID: 23792605
[TBL] [Abstract][Full Text] [Related]
20. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival.
Kidd EA; Siegel BA; Dehdashti F; Grigsby PW
Cancer; 2007 Oct; 110(8):1738-44. PubMed ID: 17786947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
